News

Homologous Recombination Deficiency (HRD) refers to a condition where a cell's ability to repair DNA double-strand breaks via the homologous recombination repair (HRR) pathway is compromised. This deficiency can lead to genomic instability, a hallmark of many cancer types. Read More

In the field of cancer genomics research, ensuring accurate and reproducible results is critical for the development and validation of high-performance assays. As genomic technologies such as Next-Generation Sequencing (NGS) continue to evolve, the demand for reliable and standardized reference materials has grown. Read More

You may hear your doctor say HRD positive or HRD negative when talking about cancer. HRD positive means your cells cannot fix DNA damage well. HRD negative means your cells fix DNA damage easily. About half of patients are in each group:Knowing your HRD status helps doctors choose your treatment. Read More

You can use HRD testing to see if a tumor cannot fix DNA. This test helps doctors pick the best treatment for you. It is very useful for ovarian, breast, and prostate cancer. Many patients with non-BRCA1/2 gene changes show HRD positivity. Germline mutations often cause even higher rates. Read More

Good fertility and good parenting are the aspirations of every family and a shared responsibility of society. The eugenics and good parenting paired standard products launched by CoBio provide strong support for precise testing and scientific intervention. Let us work together to safeguard the health and future of every new life with the power of science! Read More

Recently, CB-Gene launched a lentiviral polyclonal multi-integration site reference product with an integration frequency of 5% to 2%. It is a mixture of multiple monoclonal integration site products, covering 20 insertion sites, from 20 genes on 11 different chromosomes. Read More